New drug aims to cut Blood-Letting in rare blood cancer
NCT ID NCT05143957
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests a drug called sapablursen in 50 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. Participants currently need regular blood removal (phlebotomy) to manage their condition. The goal is to see if the drug can reduce how often phlebotomy is needed and improve symptoms like fatigue and itching.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHLEBOTOMY DEPENDENT POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Border Medical Oncology Research Unit
Albury, 2640, Australia
-
Calvary Mater Newcastle Hospital
Waratah, New South Wales, 2298, Australia
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
MICS Centrum Medyczne Toruń
Torun, 87-100, Poland
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
O'Neal Comprehensive Cancer Center University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
Oxford University Hospitals NHS Foundation Trust
Oxford, England, OX37LE, United Kingdom
-
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku
Lublin, 20-081, Poland
-
University College London Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Wojewódzki Szpital Specjalistyczny Sp. z o.o.
Słupsk, 76-200, Poland